Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 01.06.2026 UIGB IE00079WNSI6 2,591.00 GBP 68,235.98 26.336 ...
-
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company’s name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, Niagen® (patented nicotinamide riboside, or NR), the mos...
-
NICE Actimize X-Sight Enterprise Cloud Solutions Selected by DNB Norway to Transform its Fraud and Financial Crime Operations
HOBOKEN, N.J.--(BUSINESS WIRE)--NICE Actimize, a NiCE (NASDAQ: NICE) business, today announced that DNB Bank ASA, Norway’s largest financial services group, has selected NICE Actimize X-Sight Enterprise platform to modernize its fraud and financial crime operations by leveraging an array of cloud solutions designed to address the financial institution’s most pressing challenges while improving operational efficiency. This comprehensive digital transformation program is being delivered in collab...
-
Wiley Acquires Emerald, Expanding Research Scale and Deepening Proprietary Content Across the AI-Driven Knowledge Economy
HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) today announced it has acquired Emerald Publishing Limited in an all-cash transaction valued at £337 million, or USD 452 million....
-
MessageGears Expands Its Integration Ecosystem With Five New Data Sources and Destinations
ATLANTA--(BUSINESS WIRE)--MessageGears, the cross-channel marketing platform that connects directly to your data sources, today announced five new integrations: Microsoft Azure, Bynder, and SingleStore as three new data sources, and TikTok and Google Drive as two new external destinations. The additions further extend MessageGears’ flexible architecture, which allows enterprise teams to activate data across any channel or tool without duplicating, moving, or re-housing it. The announcement refl...
-
EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei’s Novel Electrolyte Acetolyte™
DUSSELDORF, Germany--(BUSINESS WIRE)--EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell which incorporates Asahi Kasei’s novel Acetolyte™....
-
QuinStreet to Participate at William Blair 46th Annual Growth Stock Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--QuinStreet, Inc. (Nasdaq: QNST), a leader in performance marketplaces and technologies for the financial services and home services industries, today announced that CEO Doug Valenti will present and host one-on-one investor meetings at the William Blair 46th Annual Growth Stock Conference at the Loews Chicago Hotel on June 4th. The Company presentation will be available via live audio webcast and archived replay on QuinStreet’s investor relations website at...
-
Berkshire Hathaway Specialty Insurance Expands Marine Leadership; Names Ben Wyatt as Head of Marine for North America and the UK
BOSTON--(BUSINESS WIRE)--BERKSHIRE HATHAWAY SPECIALTY INSURANCE EXPANDS MARINE LEADERSHIP; NAMES BEN WYATT AS HEAD OF MARINE FOR NORTH AMERICA AND THE UK...
-
Neurotech Launches “Uncovering MacTel” YouTube Channel to Support Patient Education and Awareness
CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the “Company”) announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that delivers accessible, patient-centered information for individuals affected by Macular Telangiectasia Type 2 (MacTel). Uncovering MacTel debuts with 16 short videos featuring the experiences of four individuals living with MacTel. Navigating life with a rare eye disease can be challenging. The series explores key mom...
-
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥...